Shares of ArQule Inc. of ­Woburn continued to slide after the company on Friday said a study showed the combined use of its lead drug candidate with two other cancer-fighting treatments did not meet survival targets for patients with a certain type of colorectal cancer. ArQule is engaged in the development of next-generation, small-molecule cancer therapeutics. Its products and research programs focus on key biological processes that are central to human cancers.